A phase II basket trial of dual anti‐CTLA‐4 and anti‐PD‐1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohort

20251 citationsJournal Articlegold Open Access

Authors

Young Kwang Chae · Northwestern University

Megan Othus · Data Management Services (United States)

Sandip Pravin Patel · University of California San Diego

Raid Aljumaily · OU Health

Khine Z. Win · Rideout Memorial Hospital

Tanya Pejovic · Oregon Health & Science University

Sajeve Thomas

Abstract

Two of 6 patients (33.3%) with SCCOHT achieved durable CR/iCR and long-term survival with ipilimumab plus nivolumab. Correlative studies to determine response and resistance markers are ongoing.

Topics & Keywords

Chromatin Remodeling and Cancer Neuroendocrine Tumor Research Advances Lung Cancer Research Studies

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Cancer Communications

Volume 45, Issue 8, pp. 976-986

DOI: 10.1002/cac2.70020

Field-Weighted Citation Impact: 0.81